Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
2.820
-0.190 (-6.31%)
At close: May 6, 2026, 4:00 PM EDT
2.840
+0.020 (0.71%)
After-hours: May 6, 2026, 7:58 PM EDT
Jaguar Health Revenue
In the year 2025, Jaguar Health had annual revenue of $11.51M, down -1.52%. Jaguar Health had revenue of $3.24M in the quarter ending December 31, 2025, a decrease of -7.81%.
Revenue (ttm)
$11.51M
Revenue Growth
-1.52%
P/S Ratio
0.10
Revenue / Employee
$244,915
Employees
47
Market Cap
1.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.51M | -178.00K | -1.52% |
| Dec 31, 2024 | 11.69M | 1.93M | 19.75% |
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
| Dec 31, 2018 | 4.42M | 54.96K | 1.26% |
| Dec 31, 2017 | 4.36M | 4.22M | 2,981.61% |
| Dec 31, 2016 | 141.52K | -116.86K | -45.23% |
| Dec 31, 2015 | 258.38K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionJAGX News
- 17 hours ago - Jaguar Health Stock Surges On FDA Breakthrough Discussions For Rare Disease Therapy - Benzinga
- 17 hours ago - Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) - Accesswire
- 2 days ago - Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health - Accesswire
- 7 days ago - Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs - Accesswire
- 9 days ago - Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split - Accesswire
- 12 days ago - Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) - Accesswire
- 16 days ago - Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders - Accesswire
- 23 days ago - Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs - Accesswire